Salam Reshad, Alkhafaji Amanda, Govil Dhruva, Ahmadi Fred, Affas Saif, Hassan Mona
Internal Medicine, Henry Ford Providence Hospital, Southfield, USA.
Gastroenterology, Henry Ford Providence Hospital, Southfield, USA.
Cureus. 2025 Jul 24;17(7):e88693. doi: 10.7759/cureus.88693. eCollection 2025 Jul.
Racial disparities in liver transplant outcomes remain an area of concern despite advancements in organ allocation and post-transplant care. This retrospective cohort study analyzed adult liver transplant recipients from the United Network for Organ Sharing (UNOS) registry between 1988 and 2021 to evaluate differences in graft and patient survival between African American (AA) and Caucasian American (CA) recipients. After excluding non-Black and non-White individuals and pediatric cases, a 3:1 matched cohort was created using propensity-type matching for age, sex, body mass index, and ABO type, resulting in 50,584 patients (13,421 AA and 40,263 CA). Median graft survival was significantly lower in AAs compared to CAs (1,466 vs. 1,787 days, p < 0.0001), as was median patient survival (1,480 vs. 1,815 days, p < 0.0001). Graft failure rates at one year were 2,325/12,708 (18.3%) for AA vs. 5,884/37,762 (15.6%) for CA (Chi² = 50.87, df = 1, V = 0.026, p < 0.0001); at five years, 4,326/10,323 (41.9%) vs. 10,172/30,179 (33.7%), respectively (Chi² = 218.35, V = 0.060, p < 0.0001). Similarly, mortality at five years was 3,516/9,152 (38.4%) for AA vs. 8,232/26,291 (31.3%) for CA (Chi² = 154.41, V = 0.066, p < 0.0001). AAs also had higher Model for End-Stage Liver Disease (MELD) scores at listing and transplant and were more likely to be hospitalized or in the ICU at the time of transplant. Insurance coverage differed significantly, with AAs more likely to have public insurance (6,031/12,739, 47.3% vs. 13,055/36,504, 35.8%, p < 0.0001). These findings suggest that AA liver transplant recipients experience significantly worse outcomes, likely due to a combination of advanced disease at presentation and socioeconomic disparities.
尽管在器官分配和移植后护理方面取得了进展,但肝移植结果中的种族差异仍是一个令人担忧的领域。这项回顾性队列研究分析了1988年至2021年间来自器官共享联合网络(UNOS)登记处的成年肝移植受者,以评估非裔美国人(AA)和高加索裔美国人(CA)受者在移植物和患者生存方面的差异。在排除非黑人和非白人个体以及儿科病例后,使用倾向得分匹配法对年龄、性别、体重指数和ABO血型进行3:1匹配队列,最终纳入50584例患者(13421例AA和40263例CA)。与CA相比,AA的移植物中位生存期显著更低(1466天对1787天,p<0.0001),患者中位生存期也是如此(1480天对1815天,p<0.0001)。AA组1年时的移植物失败率为2325/12708(18.3%),而CA组为5884/37762(15.6%)(卡方=50.87,自由度=1,V=0.026,p<0.0001);5年时,分别为4326/10323(41.9%)和10172/30179(33.7%)(卡方=218.35,V=0.060,p<0.0001)。同样,5年时AA的死亡率为3516/9152(38.4%),而CA为8232/26291(31.3%)(卡方=154.41,V=0.066,p<0.0001)。AA在登记和移植时的终末期肝病模型(MELD)评分也更高,并且在移植时更有可能住院或入住重症监护病房。保险覆盖情况存在显著差异,AA更有可能拥有公共保险(6031/12,739,47.3%对13,055/36,504,35.8%,p<0.0001)。这些发现表明,AA肝移植受者的结局明显更差,这可能是由于就诊时疾病进展和社会经济差异共同导致的。